Sangamo Acquisition Of Edwards’ R&D Program Will Enhance Partnering Opportunities
This article was originally published in The Pink Sheet Daily
Executive Summary
Sangamo will acquire Edwards’ angiogenesis program based on zinc finger protein activation of the VEGF gene.
You may also be interested in...
Genentech Licenses Sangamo’s DNA-Binding Technology For Protein Production
Genentech and Medarex are the only two firms with commercial licenses for the zinc finger DNA-binding protein technology.
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: